ISRCTN15358157已完成未知
Defining the feasibility and molecular impact of total diet replacement for the prevention of breast and endometrial cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 47
研究概览
简要总结
2022 Protocol article in http://dx.doi.org/10.1136/bmjopen-2021-057161 (added 05/04/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Women aged 30-50 years
- •2. BMI =30 kg/m2 or =27.5 mg/m2 in Asian and South Asian women
- •3. Pre-menopausal, with regular menstrual cycles (cycle length 21 to 40 days)
- •4. Have access to and be able to use a smartphone or tablet running iOS or Android and be able to use the Oviva app OR access and ability to use a telephone
- •5. Willing to follow the TDR using Optifast® drinks and have previously sampled them
- •6. Agree to maintain non-hormonal contraception (barrier or abstinence) until both sets of biopsies are complete and must have a negative urine pregnancy test at screening.
- •7. Women with Type 2 Diabetes Mellitus on diet +/- Metformin control can be included.
- •8. Must be able to read, understand and communicate in English
排除标准
- •1. Prior history of breast or endometrial cancer or preinvasive breast disease (Ductal Carcinoma in situ (DCiS), Lobular Carcinoma in situ (LCiS), Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH))
- •2. Any hormonal contraceptive (including progestin releasing IUCD, such as Mirena®) in the 12 weeks prior to study entry
- •3. Preventative Tamoxifen therapy within the last 6 months
- •4. Prior anti-progestin therapy (e.g. Ulipristal Acetate) within the last 6 months
- •5. Carrier of the BRCA 1 or 2 gene
- •6. Confirmed pregnant via a pregnancy test at screening, planning pregnancy in the next 12 months, or currently breast feeding
- •7. Taking prohibited medications (see Appendix 1) including warfarin or novel anticoagulants (NOAC), low molecular weight heparin (LMWH) or equivalent anti-coagulants, anti-psychotic medication, anti-diabetic medication other than Metformin
- •8. Currently on treatment with Orlistat or other pharmacological treatments for weight loss
- •9. Chronic use of steroids (more than 20mg daily of prednisolone or its equivalent)
- •10. Previously had bariatric surgery for weight loss including gastric bypass and sleeve gastrectomy
- •11. Hypersensitivity to any of the ingredients of Optifast® e.g. lactose intolerance
- •12. Allergies to the ingredients of Optifast® e.g. fish, milk, soy
- •13. Substance abuse or harmful alcohol use as indicated by a score of 16 or above on the Alcohol Use Disorders Identification Test (AUDIT)
- •14. Diagnosed with an eating disorder, or patients with severe binge eating assessed by a score of 27 or more on the Binge Eating Scale (BES)
- •15. Severe depression assessed by a score of 15 or more on the Patient Health Questionnaire-9 (PHQ-9) questionnaire.
- •16. Severe anxiety assessed by a score of 15 or more on the General Anxiety Disorder (GAD-7) questionnaire.
- •17. Psychiatric or physical comorbidity or scheduled for major surgery, which in the opinion of the treating medical physician, or the Chief Investigator (CI), would compromise their safety or adherence to the study
- •18. Lack capacity or are unable to read or understand written or verbal instructions in English
研究者
相似试验
已完成
不适用
Feasibility of the NIDUS-Professional home carer training interventioMental and Behavioural DisordersDementiaISRCTN15757555niversity College London244
已完成
Unknown
Evaluation of the feasibility and effectiveness of a health facility-based combined with home-based early childhood development (ECD) intervention in Siaya County, KenyaChild growth developmentISRCTN11561283African Population and Health Research Center699
已完成
不适用
Biofortification with zinc in flour for eliminating deficiencyZInc deficiencyISRCTN83678069niversity of Central Lancashire50
进行中（未招募）
不适用
Tessa Jowell BRAIN MATRIX - Platform StudyMalignant neoplasm of brainGliomaCancerISRCTN14218060niversity of Birmingham1,000
已完成
不适用
Movement as medicine for cardiovascular disease preventioIncreased risk of cardiovascular diseaseCirculatory SystemCardiovascular disease, unspecifiedISRCTN14582348ewcastle Upon Tyne Hospitals NHS Foundation Trust (UK)83